You are here

ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NS093756-01
Agency Tracking Number: R41NS093756
Amount: $671,659.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 105
Solicitation Number: PA14-072
Timeline
Solicitation Year: 2014
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-09-30
Award End Date (Contract End Date): 2018-06-30
Small Business Information
245 1ST ST STE 1800
Cambridge, MA 02142-1292
United States
DUNS: 079590929
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JAMES LECHLEITER
 (210) 562-4043
 lechleiter@uthscsa.edu
Business Contact
 WILLIAM KORINEK
Phone: (617) 444-8765
Email: korinek@astrocytepharma.com
Research Institution
 UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
 
BOX 20036, HOUSTON, TX 77225-0036
HOUSTON, TX 77225-0036
United States

 Nonprofit college or university
Abstract

DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit neuronal damage and cell death The proprietary approach at Astrocyte Pharmaceuticals differs significantly from historical neuroprotective attempts in that it focuses on a non neuronal cell type the astrocyte which has only recently received broader attention as an important cellular target for successful therapeutic research Molecular activation of astrocytes enhances multiple healing mechanisms including protection against edema glutamate excitotoxicity and oxidative stress Preliminary data demonstrate significant neuroprotective benefits of these molecules in mouse models when administered within minutes hours and even at hours post injury The goal of this STTR Phase I project is to establish the ability of these small molecules to significantly enhance the inherent neuroprotective activity of astrocytes in both small and large animal TBI models The project aims to optimize the treatment protocol dosing timing and frequency that maximizes the in vitro neuronal viability benefits of candidate molecules utilize an in vivo mouse TBI model to select a lead candidate that maximizes reduction in the magnitude and duration of whole brain edema and reactive gliosis biomarkers and validate that the efficacy of the lead candidate in a study with a toddler piglet TBI model PUBLIC HEALTH RELEVANCE Traumatic brain injuries TBI including concussions affect million Americans annually and are the leading cause of death and disability in children and young adults Through this grant Astrocyte Pharmaceuticals aims to develop the first therapeutic for TBI patients which would limit neural damage and the associated physical cognitive and or emotional impacts of this distressingly common injury

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government